SEATTLE, Nov. 3, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended September 30, 2010. Revenue for the third quarter ended September 30, 2010 was $20.2 million compared to $25,000 for the quarter ended September 30, 2009. Revenue for the nine months ended September 30, 2010 was $23.1 million compared to $80,000 for the nine months ended September 30, 2009.
Revenue from sales of PROVENGE® (sipuleucel-T) steadily increased month over month from $5.2 million in July, to $7.2 million in August and $7.8 million in September. In addition, revenue for October was approximately $9.5 million.
“We’re pleased with the progress we have made in the first six months of the launch of PROVENGE,” said Mitchell H. Gold, M.D., president and chief executive officer. “We look forward to making PROVENGE available to the many patients who may benefit from it and who have had very few appealing treatment options prior to the FDA approval of PROVENGE.”
Dendreon's total operating expenses for the third quarter of 2010 were $87.7 million compared to $25.8 million in the third quarter of 2009. Dendreon’s total operating expenses for the nine months ended September 30, 2010 were $213.7 million compared to $63.7 million for the same period in 2009. Total operating expenses for the three and nine months ended September 30, 2010 include a charge of $13.3 million for the settlement of litigation. The net loss for the quarter ended September 30, 2010 was $79.3 million, or $0.56 per share, which includes a $0.09 charge for the litigation settlement, compared to $45.6 million, or $0.40 per share for the quarter ended September 30, 2009, which included a non-cash charge associated with the revaluation of warrants of $19.4 million or $0.17 per share. The net loss for the nine months ended September 30, 2010 was $347.6 million, or $2.54 per share, which includes a non-cash charge associated with the revaluation of warrants of $142.6 million or $1.04 per share, compared to $187.7 million, or $1.79 per share for the nine months ended September 30, 2009, which included a non-cash charge of $122.8 million or $1.17 per share for warrant revaluation.
As of September 30, 2010, Dendreon had $392.7 million in cash, cash equivalents, and short-term and long-term investments compared to $606.4 million as of December 31, 2009.
Conference Call InformationDendreon will host a conference call today at 1:30 p.m. PT, 4:30 p.m. ET. To access the live call, dial 1-866-730-5769 (domestic) or +1-857-350-1593 (international); the conference pass code is 35737817. The call will also be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-286-8010 or +1-617-801-6888 for international callers; the conference ID number is 97336729. The replay will be available from 7:30 p.m. ET on Wednesday, November 3rd until 11:59 p.m. ET on Wednesday, November 10th. In addition, the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.
About DendreonDendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE®, was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including progress on the commercialization efforts for PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. DENDREON CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts)Three months ended September 30,Nine months ended September 30,2010200920102009(unaudited)Revenue
80Cost of revenue
7,786257,92580Operating expenses:Research and development
13,54116,49463,69841,613Selling, general and administrative
74,1359,301150,05022,126Total operating expenses
87,67625,795213,74863,739Loss from operations
(191)(606)(615)(1,930)Loss from valuation of warrant liability
-(19,371)(142,567)(122,788)Net loss before income tax benefit
(79,712)(45,551)(348,058)(187,652)Income tax benefit
(347,647)$ (187,652)Basic and diluted net loss per share
(1.79)Shares used in computation of basic anddiluted net loss per share
141,996113,447136,735105,096September 30,December 31,20102009Balance Sheet Data:Cash and cash equivalents
17,71129,441Trade accounts receivable
12,028-Prepaid antigen costs
-132,953Convertible senior subordinated notes
52,53552,535Total stockholders' equity
|SOURCE Dendreon Corporation|
Copyright©2010 PR Newswire.
All rights reserved